Palvella Therapeutics
PublicPalvella Therapeutics is now publicly traded
The data on this page reflects Palvella Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Dec 13, 2024
Est. Valuation at Exit
$195.3M
Total Funding Raised
$154.49M
Company Overview
Palvella Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with serious, rare genetic skin diseases.
Sector
Healthcare
AI Layer
Non-AI
Keywords
QTORIN rapamycin topical gelproprietary topical drug delivery platform (QTORIN)therapies for rare genetic skin diseasestopical mTOR pathway inhibitorpathogenetically targeted therapiesclinical-stage orphan drug developmenttreatment for microcystic lymphatic malformationstopical therapy with minimal systemic exposuretreatment for Pachyonychia Congenita (PC)rapamycin anhydrous gel formulationtreatment for Gorlin Syndrome (GS)treatment for cutaneous venous malformations (cVMs)biopharmaceutical for rare dermatological diseases
Palvella Therapeutics Comparables
Compare Palvella Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PellePharm | 69% | |
| AiViva BioPharma | 56% | |
| Emtora Biosciences | 56% | |
Palvella Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Dec 13, 2024 | ||||
| Grant | Oct 3, 2024 | ||||
| Series D | Jan 5, 2023 | ||||
| Series C | May 28, 2020 | ||||
| Series B | Aug 12, 2019 | ||||
Series A | Apr 12, 2019 |
Palvella Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gore Range Capital | Private Placement, Series D |
| Ligand Pharmaceuticals | Private Placement, Series C, Corporate Funding |
| Agent Capital | Series C, Series D |
| ADAR1 Capital Management | Private Placement |
| CAM Capital | Series C, Private Placement |
| Concord Biotech | Private Placement |
| Petrichor Healthcare Capital Management | Series D |
Palvella Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersWayne, Pennsylvania
Employee Range48
Year Founded2015
Last FundingDec 13, 2024
See something wrong or outdated?